CG Oncology, Inc. (CGON) Stock Forecast & Price Target

Compare

293 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CGON Analyst Ratings

Strong Buy

14 Buy

0 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Oncology, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CGON Stock 12 Month Forecast

Average Price Target

$83.17

▲(29.37% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for CG Oncology, Inc. in the last 3 months. The average price target is $83.17 with a high forecast of $108.00 and a low forecast of $65.00. The average price target represents a 29.37% change from the last price of $64.29.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","43":"$43","65":"$65","87":"$87","109":"$109"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":108,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$108.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$83.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,43,65,87,109],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.76,61.62461538461538,65.48923076923077,69.35384615384615,73.21846153846154,77.08307692307692,80.94769230769231,84.81230769230768,88.67692307692307,92.54153846153847,96.40615384615384,100.27076923076922,104.13538461538462,{"y":108,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.76,59.714615384615385,61.669230769230765,63.62384615384615,65.57846153846154,67.53307692307692,69.4876923076923,71.4423076923077,73.39692307692307,75.35153846153847,77.30615384615385,79.26076923076923,81.21538461538461,{"y":83.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.76,58.316923076923075,58.87384615384615,59.43076923076923,59.987692307692306,60.54461538461538,61.10153846153846,61.65846153846154,62.215384615384615,62.77230769230769,63.32923076923077,63.886153846153846,64.44307692307692,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.52,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.34,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.76,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$108.00

Average Price Target$83.17

Lowest Price Target$65.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Alec Stranahan

Bank of America Securities

$65

Buy

1.10%

Upside

Reiterated

03/09/26

Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Stereotaxis (STXS)

Sam Slutsky

LifeSci Capital

$108

Buy

67.99%

Upside

Reiterated

03/02/26

Buy Rating on CG Oncology Driven by PIVOT-006 Differentiation and 2026 Clinical, Regulatory Catalysts Supporting Favorable Risk–Reward

Gregory Renza

Truist Financial

$75

Buy

16.66%

Upside

Reiterated

03/02/26

Truist Financial Remains a Buy on CG Oncology, Inc. (CGON)

Robert Driscoll

Wedbush

$70→$77

Buy

19.77%

Upside

Reiterated

03/02/26

Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (NASDAQ: AUPH), MAIA Biotechnology, Inc. (NYSE MKT: MAIA) and CG Oncology, Inc. (NASDAQ: CGON)

Soumit Roy

JonesTrading

$75→$85

Buy

32.21%

Upside

Reiterated

03/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

02/27/26

CG Oncology: Advancing Creto Toward 2026 BLA with Pivotal PIVOT‑006 Catalyst and Expanding NMIBC Peak Sales Potential

Andres Y. Maldonado

H.C. Wainwright

$75→$80

Buy

24.44%

Upside

Reiterated

02/27/26

CG Oncology price target raised to $80 from $75 at H.C. WainwrightCG Oncology price target raised to $80 from $75 at H.C. Wainwright

Leonid Timashev

RBC Capital

$73

Buy

13.55%

Upside

Reiterated

02/27/26

Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), BeOne Medicines (ONC)

Bradley Canino

Guggenheim

$90

Buy

39.99%

Upside

Reiterated

02/27/26

Guggenheim Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)

Joshua Schimmer

Cantor Fitzgerald

$100

Buy

55.55%

Upside

Reiterated

02/19/26

Analysts Are Bullish on These Healthcare Stocks: CG Oncology, Inc. (CGON), Qiagen (QGEN)

Kelsey Goodwin

Piper Sandler

$70

Buy

8.88%

Upside

Reiterated

02/13/26

Piper Sandler Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)

Brian Cheng

J.P. Morgan

―

Buy

―

Reiterated

02/04/26

Analysts' Top Healthcare Picks: Cormedix (CRMD), CG Oncology, Inc. (CGON)

Corinne Johnson

Goldman Sachs

$55→$82

Buy

27.55%

Upside

Reiterated

01/12/26

CG Oncology price target raised to $82 from $55 at Goldman SachsCG Oncology price target raised to $82 from $55 at Goldman Sachs

Sean Laaman

Morgan Stanley

$89→$93

Buy

44.66%

Upside

Reiterated

01/09/26

CG Oncology price target raised to $89 from $82 at Morgan StanleyCG Oncology price target raised to $89 from $82 at Morgan Stanley

David Dai

UBS

$60

Buy

-6.67%

Downside

Reiterated

08/18/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Alec Stranahan

Bank of America Securities

$65

Buy

1.10%

Upside

Reiterated

03/09/26

Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Stereotaxis (STXS)

Sam Slutsky

LifeSci Capital

$108

Buy

67.99%

Upside

Reiterated

03/02/26

Buy Rating on CG Oncology Driven by PIVOT-006 Differentiation and 2026 Clinical, Regulatory Catalysts Supporting Favorable Risk–Reward

Gregory Renza

Truist Financial

$75

Buy

16.66%

Upside

Reiterated

03/02/26

Truist Financial Remains a Buy on CG Oncology, Inc. (CGON)

Robert Driscoll

Wedbush

$70→$77

Buy

19.77%

Upside

Reiterated

03/02/26

Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (NASDAQ: AUPH), MAIA Biotechnology, Inc. (NYSE MKT: MAIA) and CG Oncology, Inc. (NASDAQ: CGON)

Soumit Roy

JonesTrading

$75→$85

Buy

32.21%

Upside

Reiterated

03/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

02/27/26

CG Oncology: Advancing Creto Toward 2026 BLA with Pivotal PIVOT‑006 Catalyst and Expanding NMIBC Peak Sales Potential

Andres Y. Maldonado

H.C. Wainwright

$75→$80

Buy

24.44%

Upside

Reiterated

02/27/26

CG Oncology price target raised to $80 from $75 at H.C. WainwrightCG Oncology price target raised to $80 from $75 at H.C. Wainwright

Leonid Timashev

RBC Capital

$73

Buy

13.55%

Upside

Reiterated

02/27/26

Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), BeOne Medicines (ONC)

Bradley Canino

Guggenheim

$90

Buy

39.99%

Upside

Reiterated

02/27/26

Guggenheim Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)

Joshua Schimmer

Cantor Fitzgerald

$100

Buy

55.55%

Upside

Reiterated

02/19/26

Analysts Are Bullish on These Healthcare Stocks: CG Oncology, Inc. (CGON), Qiagen (QGEN)

Kelsey Goodwin

Piper Sandler

$70

Buy

8.88%

Upside

Reiterated

02/13/26

Piper Sandler Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)

Brian Cheng

J.P. Morgan

―

Buy

―

Reiterated

02/04/26

Analysts' Top Healthcare Picks: Cormedix (CRMD), CG Oncology, Inc. (CGON)

Corinne Johnson

Goldman Sachs

$55→$82

Buy

27.55%

Upside

Reiterated

01/12/26

CG Oncology price target raised to $82 from $55 at Goldman SachsCG Oncology price target raised to $82 from $55 at Goldman Sachs

Sean Laaman

Morgan Stanley

$89→$93

Buy

44.66%

Upside

Reiterated

01/09/26

CG Oncology price target raised to $89 from $82 at Morgan StanleyCG Oncology price target raised to $89 from $82 at Morgan Stanley

David Dai

UBS

$60

Buy

-6.67%

Downside

Reiterated

08/18/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CG Oncology, Inc.

3 Months

xxx

Success Rate

8/9 ratings generated profit

Average Return

+27.33%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 88.89% of your transactions generating a profit, with an average return of +27.33% per trade.

1 Year

Sean LaamanMorgan Stanley

Success Rate

7/7 ratings generated profit

Average Return

+118.80%

reiterated a buy rating 2 months ago

Copying Sean Laaman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +118.80% per trade.

2 Years

xxx

Success Rate

7/7 ratings generated profit

Average Return

+119.39%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +119.39% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CGON Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CGON has received 26 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. CGON average Analyst price target in the past 3 months is 83.17.

Each month's total comprises the sum of three months' worth of ratings.

CGON Financial Forecast

CGON Earnings Forecast

Next quarter’s earnings estimate for CGON is -$0.56 with a range of -$0.70 to -$0.49. The previous quarter’s EPS was -$0.55. CGON beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year CGON has Performed in-line its overall industry.

CGON Sales Forecast

Next quarter’s sales forecast for CGON is $293.00K with a range of $0.00 to $1.00M. The previous quarter’s sales results were $2.32M. CGON beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year CGON has Performed in-line its overall industry.

CGON Stock Forecast FAQ

What is CGON’s average 12-month price target, according to analysts?

Based on analyst ratings, CG Oncology, Inc.’s 12-month average price target is 83.17.

What is CGON’s upside potential, based on the analysts’ average price target?

CG Oncology, Inc. has 29.37% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CGON a Buy, Sell or Hold?

CG Oncology, Inc. has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.

What is CG Oncology, Inc.’s price target?

The average price target for CG Oncology, Inc. is 83.17. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $108.00 ,the lowest forecast is $65.00. The average price target represents 29.37% Increase from the current price of $64.29.

What do analysts say about CG Oncology, Inc.?

CG Oncology, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of CGON?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

CG Oncology, Inc. (CGON) Stock Forecast & Price Target

CGON Analyst Ratings

CGON Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering CG Oncology, Inc.

CGON Analyst Recommendation Trends

CGON Financial Forecast

CGON Earnings Forecast

CGON Sales Forecast

CGON Stock Forecast FAQ

Detailed List of Analyst Forecasts